PTC Therapeutics (PTCT) Company Overview

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Rick Bienkowski - Cantor Fitzgerald Eric Joseph - JPMorgan Kelly Shi - Jefferies Michael Riad - Morgan Stanley Brian Abraham - RBC Capital Markets Ellie Merle - UBS Joel Beatty - Baird Sami Corwin - William Blair Peyton Bohnsack - TD Cowen Paul Choi - Goldman Sachs Gena Wang - Barclays Danielle Brill - Raymond James Joseph Schwartz - Leerink Partners Operator Welcome to the PTC Third Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode.

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

- Opinion to be reviewed by European Commission - WARREN, N.J. , Oct. 18, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has maintained its negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne Muscular Dystrophy (nmDMD) following re-examination.

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

PTC Therapeutics announces positive results from long-term treatment studies on vatiquinone for the treatment of Friedreich ataxia.

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ron Aldridge – Senior Director of Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Kylie O'Keefe - Chief Commercial Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph – J.P. Morgan Kelly Shi – Jefferies Samantha Corwin - William Blair Brian Abraham - RBC Capital Markets Joseph Thome - TD Cowen Jeff Hung - Morgan Stanley Gena Wang – Barclays David Lebowitz – Citi Joseph Schwartz - Leerink Partners Operator Good day and thank you for standing by.

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $2.66 per share a year ago.